Suramab, a novel antiangiogenic agent, reduces tumor growth and corneal neovascularization.
about
The therapeutic effect of bevacizumab on plaque neovascularization in a rabbit model of atherosclerosis during contrast-enhanced ultrasonography.Corneal neovascularization: an anti-VEGF therapy review.Anti-vascular endothelial growth factor treatment normalizes tuberculosis granuloma vasculature and improves small molecule delivery.Comparison of the antiangiogenic activity of modified RGDRGD-endostatin to endostatin delivered by gene transfer in vivo rabbit neovascularization modelCorneal Neovascularization: A Combined Approach of Bevacizumab and Suramin Showed Increased Antiangiogenic Effect Through Downregulation of BFGF and P2X2.New insights in staging and chemotherapy of African trypanosomiasis and possible contribution of medicinal plants.
P2860
Suramab, a novel antiangiogenic agent, reduces tumor growth and corneal neovascularization.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Suramab, a novel antiangiogeni ...... nd corneal neovascularization.
@en
Suramab, a novel antiangiogeni ...... nd corneal neovascularization.
@nl
type
label
Suramab, a novel antiangiogeni ...... nd corneal neovascularization.
@en
Suramab, a novel antiangiogeni ...... nd corneal neovascularization.
@nl
prefLabel
Suramab, a novel antiangiogeni ...... nd corneal neovascularization.
@en
Suramab, a novel antiangiogeni ...... nd corneal neovascularization.
@nl
P2093
P2860
P1476
Suramab, a novel antiangiogeni ...... nd corneal neovascularization.
@en
P2093
Emiliano S Lopez
Guillermo Mazzolini
J Oscar Croxatto
Juan E Gallo
Manglio M Rizzo
P2860
P2888
P304
P356
10.1007/S00280-010-1457-Z
P577
2010-09-21T00:00:00Z